Sigma Planning Corp’s Aptose Biosciences, Inc. APTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-17,389
Closed -$54.8K 1348
2025
Q1
$54.8K Sell
17,389
-6,057
-26% -$29.5K ﹤0.01% 1181
2024
Q4
$158K Buy
23,446
+10,054
+75% +$91.6K 0.01% 1111
2024
Q3
$165K Buy
13,392
+5,576
+71% +$84.9K 0.01% 1147
2024
Q2
$178K Buy
7,816
+1,602
+26% +$54.4K 0.01% 1105
2024
Q1
$309K Buy
6,214
+3,698
+147% +$212K 0.01% 949
2023
Q4
$192K Sell
2,516
-2,344
-48% -$182K 0.02% 785
2023
Q3
$408K Buy
+4,860
New +$573K 0.02% 796
2023
Q2
Sell
-3,210
Closed -$925K 1379
2023
Q1
$925K Buy
3,210
+831
+35% +$241K 0.03% 545
2022
Q4
$621K Buy
2,379
+380
+19% +$102K 0.02% 680
2022
Q3
$535K Buy
1,999
+128
+7% +$44.1K 0.02% 706
2022
Q2
$625K Buy
1,871
+113
+6% +$54.1K 0.02% 666
2022
Q1
$1.08M Buy
1,758
+497
+39% +$275K 0.03% 507
2021
Q4
$766K Buy
1,261
+122
+11% +$115K 0.02% 659
2021
Q3
$1.12M Buy
1,139
+294
+35% +$368K 0.03% 504
2021
Q2
$1.26M Buy
845
+120
+17% +$261K 0.04% 472
2021
Q1
$1.95M Buy
725
+80
+12% +$159K 0.06% 315
2020
Q4
$1.27M Buy
645
+72
+13% +$169K 0.04% 383
2020
Q3
$1.55M Buy
573
+22
+4% +$54.9K 0.06% 300
2020
Q2
$1.56M Buy
551
+16
+3% +$51.6K 0.07% 282
2020
Q1
$1.43M Buy
535
+8
+2% +$23.9K 0.09% 246
2019
Q4
$1.34M Buy
527
+20
+4% +$26.1K 0.06% 335
2019
Q3
$476K Buy
507
+20
+4% +$22.8K 0.02% 594
2019
Q2
$572K Buy
+487
New +$448K 0.03% 509

Other funds holding APTO

Sigma Planning Corp's APTO Position: Q2 2025 in Review

Sigma Planning Corp sold out of Aptose Biosciences, Inc. (APTO) in Q2 2025, closing a stake of 17,389 shares — an estimated $54.8K sold.

Sigma Planning Corp first reported a position in APTO in Q2 2019 and held it in 23 quarters. The position peaked at $1.95M in Q1 2021. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2025.

  • Sigma Planning Corp reported no remaining Aptose Biosciences, Inc. position as of Q2 2025 after selling out during the quarter.
  • Sigma Planning Corp sold 17,389 Aptose Biosciences, Inc. shares in Q2 2025, an estimated $54.8K.
  • Sigma Planning Corp first reported a position in Aptose Biosciences, Inc. in Q2 2019 and held it in 23 quarters.
  • Sigma Planning Corp's Aptose Biosciences, Inc. position peaked at $1.95M in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2025.

Based on Sigma Planning Corp's 13F filing for Q2 2025, filed 5 Aug 2025.